The inflammation and liver cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 401-435

  Bishayee, Anupam ^a  

^a American University of Health Sciences   (United States)

Author keywords

Chemoprevention; HCC; Inflammation; Inflammatory signaling; Liver cancer; Therapy

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLCYSTEINE; ANTHOCYANIN; BERBERINE; CELECOXIB; CHRYSIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; ETODOLAC; FENRETINIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; GERANYLGERANIOL; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LYCOPENE; NIMESULIDE; PERILLYL ALCOHOL; PITAVASTATIN; POLYPHENOL; RESVERATROL; ROXITHROMYCIN; SAIKOSAPONIN D; SALIRASIB; SILIBININ; SILYMARIN; SODIUM SELENITE; SORAFENIB; TILMACOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CHRONIC INFLAMMATION; DNA DAMAGE; DNA METHYLATION; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME;

EID: 84934444266     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_16     Document Type: Article

References (202)

1. Aggarwal BB, Sung B (2011) NF-κB in cancer: a matter of life and death. Cancer Discov 1:469-471
2. Ahn B, Han BS, Kim DJ, Ohshima H (1999) Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in ra t liver tumors induced by N-nitrosodiethylamine. Carcinogenesis 20:1337-1344
3. Alwahaibi NY, Budin SB, Mohamed J, Alhamdani A (2010) Nuclear factor-kappa B as a promising target for selenium chemoprevention in rat hepatocarcinogenesis. J Gastroenterol Hepatol 25:786-791
4. Arava lli RN Steer CJ Cressman EN 2008 Molecular mechanisms of hepatocellular carcinoma Hepatology 48: 2047-2063
5. Aravalli RN, Cressman EN, Steer CJ (2013) Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 87:227-247
6. Aravindaram K, Yang NS (2010) Anti-inflammatory plant natural products for cancer therapy. Planta Med 76:1103-1117
7. Arsura M , Cavin LG (2005) Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229:157-169
8. Avila MA, Berasain C, Sangro B, Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25:3866-3884
9. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, Varki NM, Wang H, Feng GS (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19:629-639
10. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
11. Bartsch H, Montesano R (1984) Relevance of nitrosamines to human cancer. Carcinogenesis 5:1381-1393
12. Berasain C, Garcí a-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, Avila MA (2005) Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 128:424-432
13. Berasain C, Castillo J, Prieto J, Avila MA (2007) New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27:174-185
14. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA (2009a ) Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 1155:206-221
15. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaría M, Prieto J, Avila MA (2009 b ) The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med 234:713-725
16. Bishayee A (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2:409-418
17. Bishayee A (2012) Editorial: recent advances in the prevention and therapy of hepatocellular carcinoma. Curr Cancer Drug Targets 12:1043-1044
18. Bishayee A (2013) β-Catenin: a novel biomarker and therapeutic target in liver cancer. In: Georgakilas A (ed) Cancer biomarkers. CRC Press, Boca Raton, pp 51-75
19. Bishayee A, Dhir N (2009) Resv eratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 179:131-144
20. Bishayee A, Politis T, Darvesh AS (2010a) Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 36:43-53
21. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, Darvesh AS (2010 b) Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 27:1080-1091
22. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carroll RT (2010c) Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 3:753-763
23. Bishayee A, Mbimba T, Thoppil RJ, Háznagy-Rad nai E, Sipos P, Darvesh AS, Folkesson H, Hohmann J (2011a) Anthocyanin-rich black currant (Ribes nigrum L.) extract affords chemoprevention against diethylnitrosamine-induced hepatocellular carcinogenesis in rats. J Nutr Biochem 22:1035-1046
24. Bishayee A, Bhatia D, Thoppil RJ, Darvesh AS, Nevo E, Lansky EP (2011b) Pomegranatemediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms . Carcinogenesis 32:888-896
25. Bishayee A, Thoppil RJ, Waghray A, Kruse JA, Novotny NA, Darvesh AS (2012) Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in viv o evidence, molecular targets, and clinical relevance. Curr Cancer Drug Targets 12:1191-1232
26. Bishayee A, Thoppil RJ, Mandal A, Darvesh AS, Ohanyan V, Meszaros JG, Háznagy-Radnai E, Hohmann J, Bhatia D (2013a) Black currant phytoconstituents exert chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis by suppression of the inflammatory response. Mol Carcinog 52:304-317
27. Bishayee A, Thoppil RJ, Darvesh AS, Ohanyan V, Meszaros JG, Bhatia D (2013b) Pomegranate phytoconstituents blunt the inflammatory cascade in a chemically induced rodent model of hepatocellular carcinogenesis. J Nutr Biochem 24:178-187
28. Blonski W, Kotlyar DS, Forde KA (2010) Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 16:3603-3615
29. Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. Semin Onccol 38:752-763
30. Brownell J, Polyak SJ (2013) Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 19:1347-1352
31. Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80:1197-1213
32. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117-1128
33. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM (2008) Aberrant iNOS signaling is und er genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 29:1639-1647
34. Castillo J, Erroba E, Perugorr ía MJ, Santamaría M, Lee DC, Prieto J, Avila MA, Berasain C (2006) Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66:6129-6138
35. Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 20:2362-2368
36. Cervello M, Montalto G (2006) Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 12:5113-5121
37. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
38. Chiang SH, Bazuin e M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR (2009) The protein kinase IKKepsilon regulates energy balance in obese mic e. Cell 138:961-975
39. Chuang SE, Cheng AL, Lin JK, Kuo ML (2000) Inhibition by curcumin of diethylnitrosamineinduced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related protein s in rats. Food Chem Toxicol 38:991-995
40. Chuma M, Hige S, Nakanishi M, Ogawa K, Natsuizaka M, Yamamoto Y, Asaka M (2008) 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepat ocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 23:1431-1436
41. Costa RH, Kalinichenko VV, Holterman AX, Wang X (2003) Transcription factors in liver development, differentiation, and regeneration. Hepatology 38:1331-1347
42. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
43. Cui W, Gu F, Hu K (2009) Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 15:1943-1950
44. Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T (2008) Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J Cell Physiol 214:371-380
45. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421
46. Darvesh AS, Bishayee A (2010) Selenium in the prevention and treatment of hepatocellular carcinoma. Anticancer Agents Med Chem 10:338-345
47. Darvesh AS Bishayee A 2013 Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer Nutr Cancer 65: 329-344
48. Darvesh AS, Aggarwal BB, Bishayee A (2012) Curcumin and liver cancer: a review. Curr Pharm Biotechnol 13:218-228
49. Davies RA, Knight B, Tian YW, Yeoh GC, Olynyk JK (2006) Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor. Carcinogenesis 27: 1607-1616
50. de Almagro MC, Vucic D (2012) The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 34:200-211
51. Denda A, Kitayama W, Murata A, Kishida H, Sasaki Y, Kusuoka O, Tsujiuchi T, Tsutsumi M, Nakae D, Takagi H, Konishi Y (2002) Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis 23:245-256
52. Denda A, Kitayama W, Kishida H, Murata N, Tamura K, Kusuoka O, Tsutsumi M, Nishikawa F, Kita E, Nakae D, Konishi Y, Kuniyasu H (2007) Expression of inducible nitric oxide (NO) synthase but not prevention by its gene ablation of hepatocarcinogenesis with fibrosis caused by a choline-d eficient, L-amino acid-defined diet in rats and mice. Nitric Oxide 16:164-176
53. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33:335-351
54. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E (1989) High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines p roduction. Clin Exp Immunol 77:221-225
55. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107
56. DiDonato JA, Mercurio F, Karin M (2012) NF-κB and the link between inflammation and cancer. Immunol Rev 246:379-400
57. Dutkowski P, De Rougemont O, M üllhaupt B, Clavien PA (2010) Current and future trends in liver transplantation in Europe. Gastroenterology 138:802-809
58. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27-S34
59. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369-380
60. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576
61. Espindola RM, Mazzantini RP, Ong TP, de Conti A, Heido r R, Moreno FS (2005) Geranylgeraniol and β-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-κB activa tion. Carcinogenesis 26:1091-1099
62. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687
63. Futakuchi M, Ogawa K , Sano M, Tamano S, Takeshita F, Shirai T (2002) Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma. Jpn J Cancer Res 93:1175-1181
64. Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, Xiang YB (2012) Risk factors of hepatocellular carcinoma: current status and perspectives. Asian Pac J Cancer Prev 13:743-752
65. Ghosh S, Karin M (2002) Missing pieces in the NF-κB puzzle. Cell 109:S81-S96
66. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L, D'Alessandro N, Cervello M, Montalto G (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann NY Acad Sci 1155:293-299
67. Gramantieri L, Fornari F, Callegari E, Sabbioni S , Lanza G, Croce CM, Bolondi L, Negrini M (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189-2204
68. Gregor MF Hotamisligil GS 2011 Inflammatory mechanisms in obesity Annu Rev Immunol 29: 415-445
69. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
70. Gupta SC, Kim JH, Prasad S, Aggarw al BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29:405-434
71. Guicciardi ME, Mott JL, Bronk SF, Kurita S, Fingas CD, Gores GJ (2011) Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res 317:1 07-116
72. Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10:561-574
73. Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, Tsukamoto H (2004) Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 279:4820-4828
74. Han C, Michalopoulos GK, Wu T (2006) Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207:261-270
75. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos D (2011) An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147:1233-1247
76. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M (2009) A lymphotoxin-driven pa thway to hepatocellular carcinoma. Cancer Cell 16:295-308
77. Heydtmann M, Adams DH (2009) Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 49:676-688
78. He G, Karin M (2011) NF-κB and STAT3: key players in liver inflammation and cancer. Cell Res 21:159-168
79. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17:286-297
80. Hoffmann A, Baltimore D (2006) Circuitry of nuclear factor kappaB signaling. Immunol Rev 210:171-186
81. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM (2010) Molecular classification and novel tar gets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35-51
82. Huang F, Geng XP (2010) Chemokines and hepatocellular carcinoma. World J Gastroenterol 16:1832-1836
83. Huynh H (2010) Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 80:550-560
84. Je Y, Schutz FAB, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor rece ptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and metaanalysis of clinical trials. Lancet Oncol 10:967-974
85. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437-147
86. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1:a000141
87. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663
88. Kawanishi S, Hiraku Y, Pinlaor S, Ma N (2006) Oxidativ e and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387:365-372
89. Kenya PR (1990) Oral contraceptives use and liver tumours: a review. East Afr Med J 67:146-153
90. Khan MS, Devaraj H, Devaraj N (2011) Chrysin abrogates early hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine-induced preneoplastic nodules in rats. Toxi col Appl Pharmacol 251:85-94
91. Kim SF, Huri DA, Snyder SH (2005) Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310:1966-1970
92. Kim YS , Young MR, Bobe G, Colburn NH, Milner JA (2009) Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res 2:200-208
93. Kota J, Chivukula RR, O'Donnell KA, Wen tzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic micro-RNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017
94. Kuo PC, Abe KY, Schroeder RA (1997) Oxidative stress increases hepatocyte iNOS gene transcription and promoter activity. Biochem Biophys Res Commun 234:289-292
95. Korula J , Yellin A, Kanel G, Campofiori G, Nichols P (1991) Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 155:416-418
96. Lachenmayer A, Alsinet C, Chang CY, Llovet JM (2010) Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 42:S264-S272
97. Lang K, Danchenko N, Gondek K, Shah S, Thompson D (2009) The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50:89-99
98. Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97:1005-1008
99. Lee Y, Park US, Choi I, Yoon SK, Park YM, Lee YI (1998) Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepato ma cells. Clin Cancer Res 4:1711-1717
100. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H (2009) Persistently activated Stat3 maintains consti tutive NF-kappaB activity in tumors. Cancer Cell 15:283-293
101. Liu W, Nakamura H, Tsujimura T, Cheng J, Yamamoto T, Iwamoto Y, Imanishi H, Shimomura S, Yamamoto T, Hirasawa T, Inagaki S, Nishiguchi S, Hada T (2006) Chemoprevention of spontaneous develop ment of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 97:768-773
102. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Hä ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, S HARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
103. Lu SC (2010) Where are we in the chemoprevention of hepatocellular carcinoma? Hepatology 51:734-736
104. Lu XL, He SX, Ren MD, Wang YL, Zhang YX, Liu EQ (2012) Chemopreventive effect of saikosaponin-d on diethylinitrosamine-induced hepatocarcinogenesis: involvement of CCAAT/enhancer binding protein ? and cyclo oxygenase-2. Mol Med Rep 5:637-644
105. Luedde T, Schwabe RF (2011) NF-κB in the liver: linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8:108-118
106. Lue dde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11:119-132
107. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, Sun X, Jiang H (2011) Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt a nd nuclear factor-αB. Cancer Lett 301:75-84
108. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKα couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical he patocarcinogenesis. Cell 121:977-990
109. Maeda S, Hikiba Y, Sakamoto K, Nakagawa H, Hirata Y, Hayakawa Y, Yanai A, Ogura K, Karin M, Omata M (2009) Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 50:1851-1860
110. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, Rose-John S, Della Rocca C, Tripodi M, Lazzaro D, Taub R, Savino R, Ciliberto G (1998) Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 17:5588-5597
111. Mantovani A Allavena P Sica A Balkwill F 2008 Cancer-related inflammation Nature 454: 436-444
112. Markiewski MM, DeAngelis RA, Lambris JD (2006) Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 43:45-56
113. Má rquez-Rosado L, Trejo-Solís MC, García- Cuéllar CM, Villa-Trevino S (2005) Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43:653-660
114. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlo ngano R, Accardo M, Agresti M, Caraglia M, Sperlongano P (2011) Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 9:171
115. Marrero CR, Marrero JA (2007) Viral hepatitis and hepatocellular carcinoma. Arch Med Res 38:612-620
116. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46:48-57
117. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP et al (1994) Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145:1237-1245
118. Mauriz JL, Linares P, Macias RI, Jorquera F, Honrado E, Olcoz JL, González P, Gonzá lez-Gallego J (2003) TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor kappa B activation in a rat model of hepatocellular carcinoma. Free Radic Res 37:841-848
119. Mbimba T, Awale P, Bhatia D, Geldenhuys WJ, Darvesh AS, Carroll RT, Bishayee A (2012) Alteration of hepatic proinflammatory cytokines is involved in the res veratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol 13:229-234
120. McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, Hamid Q, Radomski MW (2002) Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 99:17161-17166
121. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC (2010) IAP regulation of metastasis. Cancer Cell 17:53-64
122. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL (1995) Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55:979-983
123. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z (2002) Dominant role of hepatitis B virus and co factor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36:1214-1220
124. Murakami A (2009) Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. Forum Nutr 61:193-203
125. Muriel P (2009) NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol 29:91-100
126. Murillo MM, Carmona-Cuenca I, Del Castillo G, Ortiz C, Roncero C, Sánchez A, Ferná ndez M, Fabregat I (2007) Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism. Biochem J 405:251-259
127. Murugan RS, Priyadarsini RV, Ramalingam K, Hara Y, Karunagaran D, Nagini S (2010) Intrinsic apoptosis and NF-κB signaling are potential molecular targets for chemoprevention by black tea polyphenols in HepG2 cells in vitro and in a rat hepatocarcinogenesis model in vivo. Food Chem Toxicol 48:3281-3287
128. Nakagawa H, Maeda S (2012) Inflammation-and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol 18:4071-4081
129. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M (2009) Serum IL-6 levels and the risk for hepatocarcinogenesis in c hronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 125:2264-2269
130. Nair S, Mason A, Eason J, Loss G, Perrillo RP (2002) Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36:150-155
131. Naugler WE, Karin M (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:109-119
132. Naugler WE Sakurai T Kim S Maeda S Kim K Elsharkawy AM Karin M 2007 Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 317: 121-12 4
133. Nejak-Bowen KN, Monga SP (2011) Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21:44-58
134. Nishikawa-Ogawa M, Wanibuchi H, Morimura K, Kinoshita A, Nishikawa T, Hayashi S, Yano Y, Fukushima S (2006) N-acetylcysteine and S-methylcysteine inhibit MeIQx rat hepatocarcinogenesis in the post-initiation stage. Carcinogenesis 27:982-988
135. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42:S206-S214
136. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K, Takaesu G, Maehara Y, Iida M, Yoshimura A (2006) Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131: 179-193
137. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866
138. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208
139. Pfitzner E, Kliem S, Baus D, Litterst CM (2004) The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 10:2839-2850
140. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Uriel i-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466
141. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderso n BE, Wogan GN, Groopman JD (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3-10
142. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N (2001) Coexpression of inducible nitric oxide synthase and COX-2in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7:1325-1332
143. Ramakrishnan G, Raghavendran HRB, Vinod hkumar R, Devaki T (2006) Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem-Biol Interact 161:104-114
144. Ramakrishnan G, Elinos-Bá ez CM, Jagan S, Augustine TA , Kamaraj S, Anandakumar P, Devaki T (2008) Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem 313:53-61
145. Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, Boussahmain C, Cormier KS, Fox JG (2007) Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 67:11536-11546
146. Ruggieri A, Barbati C, Malorni W (2010) Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer 127:499-504
147. Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Tanaka K (2008) Interaction between interleukin-1?-31T/C gene polymorphism and dr inking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett 271:98-104
148. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M (2008) Hepatocyte ne crosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-165
149. Schneider-Merck T, Borbath I, Charette N, De Saeger C, Abarca J, Leclercq I, Horsmans Y, Stä rkel P (2009) The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer 45:2050-2060
150. Schü tte K, Bornschein J, Malfertheiner P (2009) Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 27:80-92
151. Sengupta S, Bishayee A (2010) Micro RNAs in cancer therapy: from bench to bedside. Curr Cancer Ther Rev 6:157-162
152. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399
153. Senthil M, Mailey B, Leong L, Chung V, Yen Y, Chen YJ, Marx H, Kim J (2010) Liver-directed regional therapy in the multi-disciplinary management of hepatocellular cancer. Cur r Cancer Ther Rev 6:19-25
154. Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25:143-154
155. Shimizu M, Sakai H, Shirakami Y, Ya suda Y, Kubota M, Terakura D, Baba A, Ohno T, Hara Y, Tanaka T, Moriwaki H (2011a) Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev Res 4:396-403
156. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, Takai K, Tsurumi H, Tanaka T, Moriwaki H (2011b) Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-+(db)/+Lepr(db) mice. Cancer Prev Res 4:128-136
157. Shimizu M, Yasuda Y, Sakai H, Kubota M, Terakura D, Baba A, Ohno T, Kochi T, Tsurumi H, Tanaka T, Moriwaki H (2011c) Pit avastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 11:281
158. Shimizu M, Tanaka T, Moriwaki H (2013) Obesity and hepatocellular carcinoma: targeting ob esity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 35:191-202
159. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, Kawasak i H (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46:407-412
160. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. Clin Invest 116:1793-1801
161. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M (2007) The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75:770-787
162. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer
163. Silke J, Meier P (2013) Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol 5: a008730
164. Simile MM, Pagnan G, Pastorino F, Brignole C, De Miglio MR, Muroni MR, Asara G, Frau M, Seddaiu MA, Calvisi DF, Feo F, Ponzoni M, Pascale RM (2005) Chemopreventive N-(4-hydroxyphenyl) retinamide (fenretinide) targets deregulated NF-κB and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 26:417-427
165. Sivaramakrishnan V, Niranjali Devaraj S (2009) Morin regulates the expression of NF-κB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma. Chem Biol Interact 180:353-359
166. Sivaramakrishnan V, Niranjali Devaraj S (2010) Morin fosters apoptosis in experimental hepatocellular carcinogenesis model. Chem Biol Interact 183:284-292
167. Stä rkel P, Charette N, Borbath I, Schneider-Merck T, De Saeger C, Abarca J, Leclercq I, Horsmans Y (2012) Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Mol Carcinog 51:816-825
168. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G (201 3) Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 1835:46-60
169. Sun B, Karin M (2012) Obesity, inflammation, and liver cancer. J Hepatol 56:704-713
170. Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK (2004) The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 17:35-38
171. Szabo G, Lippai D (2012) Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis 30:243-248
172. Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, Iwasa M, Ma N, Kawanishi S, Watan abe S, Kaito M, Takei Y (2008) Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 98:580-586
173. Taub R (2003) Hepatoprotect ion via the IL-6/Stat3 pathway. J Clin Invest 112:978-980
174. Thoppil RJ Bhatia D Barnes KF Háznagy-Radnai E Hohmann J Darvesh AS Bishayee A 2012 Black currant anthocyanins abrogate oxidativ e stress through Nrf2-mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma Curr Cancer Drug Targets 12: 1244-1257
175. Ueno S, Aoki D, Kubo F, Hiwatashi K, Matsushita K, Oyama T, Mar uyama I, Aikou T (2005) Roxithromycin inhibits constitutive activation of nuclear factor & #x03BA;B by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res 11:5645-5650
176. Wai PY, Kuo PC (2012) Intersecting pathways in inflammation and cancer: hepatocellular carcinoma as a paradigm. World J Clin Oncol 10:15-23
177. Wang LY, Chen CJ, Zhang YJ, Tsai WY, Lee PH, Feitelson MA, Lee CS, Santella RM (1998) 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol 147:315-323
178. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M (2003) Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37 :65-71
179. Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD (2009a ) Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int J Cancer 124:540-546
180. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST (2009b ) Role of microRNA-155 at early stages of hepatocarcinog enesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 50:1152-1161
181. Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD (2010) Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int J Cancer 126:178 8-1796
182. Weber A, Boege Y, Reisinger F, Heikenwälder M (2011) Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med Wkly 141:w13197
183. Weinhold B, Rüther U ( 1997) Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene. Biochem J 327:425-429
184. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
185. West AP, Koblansky AA, Ghosh S (2006) Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 22:409-437
186. White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S (2012) Medica l care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 10:547-554
187. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989-5005
188. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103:1372-1379
189. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916
190. Wilson JF (2005) Liver cancer on the rise. Ann Intern Med 142:1029-1032
191. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL (2009) High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 124:2766-2770
192. Wong CM, Kai AK, Tsang FH, Ng IO (2013) Regulation of hepatocarcinogenesis by microRNAs. Front Biosci 5:49-60
193. Wu T (2005) Cycloygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 1755:135-150
194. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32:28-44
195. Wunderlich FT Luedde T Singer S Schmidt-Supprian M Baumgartl J Schirmacher P Pasparakis M Brü ning JC 2008 Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis Proc Natl Acad Sci USA 105:1297-1302
196. Xiao C, G hosh S (2005) NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol 560:41-45
197. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M (2003) JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liv er fibrosis. Gastroenterology 125:556-571
198. Yildirim Y, Ozyilkan O, Bilezikci B, Akcali Z, Haberal M (2008) Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival. Asian Pac J Cancer Prev 9:295-298
199. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7:454-465
200. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S (2006) Effects of curcumi n on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 34:109-115
201. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
202. Zhao X, Zhang JJ, Wang X, Bu XY, Lou YQ, Zhang GL (2008) Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine-and phenobarbital-treated rats. Biomed Pharmacother 62:567-572